Discover what sets IXICO PLC (LSE:IXI, OTC:PHYOF) apart from competitors. CEO Bram Goorden highlights the company’s exclusive focus on neurodegenerative diseases, its proven track record in biomarkers, and how decades of regulatory expertise make it a trusted partner.
Click the link in the video, or visit the IXICO profile to view the full interview.
#Neuroscience #CNS #Biomarkers #ClinicalResearch #LifeSciences #IXICO #Neuroimaging #AlzheimersResearch #ParkinsonsDisease #AIDrivenHealthcare #Biomarkers #ClinicalResearch #HealthcareInnovation #UKStocks #BramGoorden #ProactiveInvestors #MedicalAI #LifeSciences #PostMarketingSurveillance #AI #AIinHealthcare #Alzheimers #Parkinsons #BiotechInnovation